Equities

TELA Bio Inc

TELA:NMQ

TELA Bio Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)3.11
  • Today's Change0.17 / 5.78%
  • Shares traded239.10k
  • 1 Year change-32.68%
  • Beta0.9728
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy1
Outperform4
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 5 analysts offering 12 month price targets for TELA Bio Inc have a median target of 9.00, with a high estimate of 12.00 and a low estimate of 5.00. The median estimate represents a 189.39% increase from the last price of 3.11.
High285.9%12.00
Med189.4%9.00
Low60.8%5.00

Earnings history & estimates in USD

On Nov 07, 2024, TELA Bio Inc reported 3rd quarter 2024 losses of -0.42 per share. This result was in line with the consensus of the 5 analysts following the company and exceeded last year's 3rd quarter results by 6.67%.
The next earnings announcement is expected on Mar 19, 2025.
Average growth rate-16.32%
TELA Bio Inc reported annual 2023 losses of -2.04 per share on Mar 21, 2024.
Average growth rate+22.64%
More ▼

Revenue history & estimates in USD

TELA Bio, Inc. had 3rd quarter 2024 revenues of 18.96m. This bettered the 18.85m consensus of the 5 analysts covering the company. This was 59.18% above the prior year's 3rd quarter results.
Average growth rate+6.33%
TELA Bio, Inc. had revenues for the full year 2023 of 58.45m. This was 41.13% above the prior year's results.
Average growth rate+40.35%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.